Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

In obese rodents, excess myocardial lipid accumulation (lipotoxicity) of myocardium may cause cardiomyopathy that in the obese Zucker diabetic fatty (ZDF) fa/fa rat can be prevented by treatment with troglitazone (TGZ). To determine the underlying mechanisms, we measured total 5′-AMP-activated kinase (AMPK) protein and its activated, phosphorylated form, P-AMPK. P-AMPK was significantly reduced in both ZDF fa/fa rat and ob/ob mouse hearts compared with lean, wild-type controls. TGZ treatment of obese ZDF rats, which lowered cardiac lipid content, increased P-AMPK. Expression of protein phosphatase 2C (PP2C), which inactivates AMPK activity by dephosphorylation, was increased in untreated ZDF fa/fa rat hearts, but fell with TGZ treatment, suggesting that PP2C can influence AMPK activity. In cultured myocardiocytes, fatty acids reduced P-AMPK, suggesting a feed-forward effect of lipid overload. Our findings highlight a role of PP2C and AMPK in the derangements of cardiac lipid metabolism in obedity and provide new insights as to the mechanisms of the liporegulatory disorder leading to lipotoxic cardiomyopathy.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume288
Issue number1 51-1
DOIs
StatePublished - Jan 2005

Fingerprint

troglitazone
AMP-Activated Protein Kinases
Phosphoprotein Phosphatases
Rodentia
Lipids
Rats
Cardiomyopathies
Protein Phosphatase 2C
Lipid Metabolism

Keywords

  • Adenosine 5′-monophosphate-activated kinase
  • Diabetes
  • Heart
  • Obesity
  • Protein phosphatase 2C

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Biochemistry

Cite this

@article{4741144f53ad4670ae58b12098866767,
title = "Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone",
abstract = "In obese rodents, excess myocardial lipid accumulation (lipotoxicity) of myocardium may cause cardiomyopathy that in the obese Zucker diabetic fatty (ZDF) fa/fa rat can be prevented by treatment with troglitazone (TGZ). To determine the underlying mechanisms, we measured total 5′-AMP-activated kinase (AMPK) protein and its activated, phosphorylated form, P-AMPK. P-AMPK was significantly reduced in both ZDF fa/fa rat and ob/ob mouse hearts compared with lean, wild-type controls. TGZ treatment of obese ZDF rats, which lowered cardiac lipid content, increased P-AMPK. Expression of protein phosphatase 2C (PP2C), which inactivates AMPK activity by dephosphorylation, was increased in untreated ZDF fa/fa rat hearts, but fell with TGZ treatment, suggesting that PP2C can influence AMPK activity. In cultured myocardiocytes, fatty acids reduced P-AMPK, suggesting a feed-forward effect of lipid overload. Our findings highlight a role of PP2C and AMPK in the derangements of cardiac lipid metabolism in obedity and provide new insights as to the mechanisms of the liporegulatory disorder leading to lipotoxic cardiomyopathy.",
keywords = "Adenosine 5′-monophosphate-activated kinase, Diabetes, Heart, Obesity, Protein phosphatase 2C",
author = "May-Yun Wang and Unger, {Roger H}",
year = "2005",
month = "1",
doi = "10.1152/ajpendo.00004.2004",
language = "English (US)",
volume = "288",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1 51-1",

}

TY - JOUR

T1 - Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone

AU - Wang, May-Yun

AU - Unger, Roger H

PY - 2005/1

Y1 - 2005/1

N2 - In obese rodents, excess myocardial lipid accumulation (lipotoxicity) of myocardium may cause cardiomyopathy that in the obese Zucker diabetic fatty (ZDF) fa/fa rat can be prevented by treatment with troglitazone (TGZ). To determine the underlying mechanisms, we measured total 5′-AMP-activated kinase (AMPK) protein and its activated, phosphorylated form, P-AMPK. P-AMPK was significantly reduced in both ZDF fa/fa rat and ob/ob mouse hearts compared with lean, wild-type controls. TGZ treatment of obese ZDF rats, which lowered cardiac lipid content, increased P-AMPK. Expression of protein phosphatase 2C (PP2C), which inactivates AMPK activity by dephosphorylation, was increased in untreated ZDF fa/fa rat hearts, but fell with TGZ treatment, suggesting that PP2C can influence AMPK activity. In cultured myocardiocytes, fatty acids reduced P-AMPK, suggesting a feed-forward effect of lipid overload. Our findings highlight a role of PP2C and AMPK in the derangements of cardiac lipid metabolism in obedity and provide new insights as to the mechanisms of the liporegulatory disorder leading to lipotoxic cardiomyopathy.

AB - In obese rodents, excess myocardial lipid accumulation (lipotoxicity) of myocardium may cause cardiomyopathy that in the obese Zucker diabetic fatty (ZDF) fa/fa rat can be prevented by treatment with troglitazone (TGZ). To determine the underlying mechanisms, we measured total 5′-AMP-activated kinase (AMPK) protein and its activated, phosphorylated form, P-AMPK. P-AMPK was significantly reduced in both ZDF fa/fa rat and ob/ob mouse hearts compared with lean, wild-type controls. TGZ treatment of obese ZDF rats, which lowered cardiac lipid content, increased P-AMPK. Expression of protein phosphatase 2C (PP2C), which inactivates AMPK activity by dephosphorylation, was increased in untreated ZDF fa/fa rat hearts, but fell with TGZ treatment, suggesting that PP2C can influence AMPK activity. In cultured myocardiocytes, fatty acids reduced P-AMPK, suggesting a feed-forward effect of lipid overload. Our findings highlight a role of PP2C and AMPK in the derangements of cardiac lipid metabolism in obedity and provide new insights as to the mechanisms of the liporegulatory disorder leading to lipotoxic cardiomyopathy.

KW - Adenosine 5′-monophosphate-activated kinase

KW - Diabetes

KW - Heart

KW - Obesity

KW - Protein phosphatase 2C

UR - http://www.scopus.com/inward/record.url?scp=11144283125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144283125&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00004.2004

DO - 10.1152/ajpendo.00004.2004

M3 - Article

C2 - 15367397

AN - SCOPUS:11144283125

VL - 288

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 1 51-1

ER -